论文部分内容阅读
近来,癌症患者血浆/血清中肿瘤DNA的临床意义和生物学特性引起了人们的广泛注意。同样,人们对宫颈癌患者血浆/血清中的人类乳头状瘤病毒(HPV)的DNA亦作了研究。研究采用不同的检测标本(血浆/血清)、不同的DNA抽提方式及不同的引物来检测循环游离HPV DNA,所得的阳性率从6.9%~50%不等。因为宫颈癌患者血浆/血清中的HPV DNA很可能来源于肿瘤本身,这给我们提供了一个新的宫颈癌治疗后的监测工具,特别是针对晚期的患者。可以预测,这一极具有应用前景的分子肿瘤标志物不久将会在临床上被广泛应用。
Recently, the clinical significance and biological properties of tumor DNA in plasma / serum of cancer patients have drawn much attention. Similarly, the DNA of human papilloma virus (HPV) in the plasma / serum of cervical cancer patients has also been studied. Study using different test specimens (plasma / serum), different DNA extraction methods and different primers to detect circulating free HPV DNA, the positive rate obtained from 6.9% to 50%. Because the HPV DNA in the plasma / serum of cervical cancer is likely to be derived from the tumor itself, this provides us with a new monitoring tool for post-treatment cervical cancer, especially for advanced patients. Predictably, this very promising molecular tumor marker will soon be widely used clinically.